BIRC5 and hepatocellular carcinoma: Moreover, Sun et al. found that sorafenib enhanced the accumulation and activation of nucleus YAP, thereby promoting the resistance of sorafenib by inhibiting apoptosis of HCC cells through the downstream mediator of YAP and survivin [50].